Statins and prevention of venous thromboembolism: Myth or reality?

Archives of Cardiovascular Diseases
Sébastien GaertnerDominique Stephan

Abstract

The pleiotropic effects of statins, beyond their cholesterol-lowering properties, are much debated. In primary prevention, several observational cohort and case-control studies appear to show that statins reduce the incidence of venous thromboembolism by about 30%. In a single randomized placebo-controlled clinical trial (JUPITER), which included 17,000 patients, rosuvastatin 20mg/day reduced the risk of venous thromboembolism by 43%. However, these patients were at low risk of venous thromboembolism, and the frequency of the event was, in principle, low. In secondary prevention, several observational studies and post-hoc analyses of randomized clinical trials have suggested that statins may prevent recurrence of venous thromboembolism. However, none of these studies had enough scientific weight to form the basis of a recommendation to use statins for secondary prevention. The putative preventive effect of statins appears to be independent of plasma cholesterol concentration and could be a pharmacological property of the statin class, although a dose-effect relationship has not been demonstrated. The mechanism through which statins might prevent venous thrombosis is thought to involve their anti-inflammatory and antioxidant eff...Continue Reading

References

Aug 3, 2001·Archives of Internal Medicine·J G RayA Laupacis
Apr 11, 2003·The New England Journal of Medicine·Paolo PrandoniAntonio Girolami
Jul 25, 2003·The New England Journal of Medicine·Murali K DuggiralaKaren F Mauck
Apr 22, 2004·Journal of Thrombosis and Haemostasis : JTH·C J M DoggenB M Psaty
Apr 22, 2004·Journal of Thrombosis and Haemostasis : JTH·N K KabaUNKNOWN THROMBO Investigators
Jul 27, 2005·Circulation·Sucharita Sen-BanerjeeMukesh K Jain
Jul 14, 2006·Journal of Thrombosis and Haemostasis : JTH·L M ReichM Cushman
Sep 12, 2006·Journal of Thrombosis and Haemostasis : JTH·P B van der HagenM Cushman
Dec 19, 2007·Circulation·Walter AgenoPieter W Kamphuisen
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Nov 28, 2008·Journal of Thrombosis and Haemostasis : JTH·A S RamcharanC J M Doggen
Mar 31, 2009·The New England Journal of Medicine·Robert J GlynnPaul M Ridker
Dec 25, 2009·European Heart Journal·Alessandro SquizzatoWalter Ageno
Aug 19, 2010·International Journal of Clinical Practice·V AgarwalC I Coleman
Nov 17, 2011·The New England Journal of Medicine·Stephen J NichollsSteven E Nissen
Nov 6, 2012·The New England Journal of Medicine·Timothy A BrightonUNKNOWN ASPIRE Investigators
Feb 12, 2013·European Heart Journal·Sara Biere-RafiPieter W Kamphuisen
Apr 16, 2013·European Heart Journal·Kausik K Ray
Nov 2, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Erin M HaldJohn-Bjarne Hansen
May 14, 2014·Journal of Thrombosis and Haemostasis : JTH·M SchmidtH T Sørensen

❮ Previous
Next ❯

Citations

Mar 8, 2017·Current Opinion in Cardiology·Vanessa BianconiMatteo Pirro
Jul 21, 2017·Expert Review of Cardiovascular Therapy·Setor K KunutsorJari A Laukkanen
Jun 24, 2017·Anesthesia and Analgesia·Ronald J Gordon, Frederick W Lombard
Jun 29, 2021·Thrombosis Journal·Mohammadreza BordbarWillem M Lijfering

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.